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The Epidemiology of Leber Hereditary Optic Neuropathy in the North East
of England
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We performed the first population-based clinical and molecular genetic study of Leber hereditary optic neuropathy
(LHON) in a population of 2,173,800 individuals in the North East of England. We identified 16 genealogically
unrelated families who harbor one of the three primary mitochondrial DNA (mtDNA) mutations that cause LHON.
Two of these families were found to be linked genetically to a common maternal founder. A de novo mtDNA
mutation (G3460A) was identified in one family. The minimum point prevalence of visual failure due to LHON
within this population was 3.22 per 100,000 (95% CI 2.47–3.97 per 100,000), and the minimum point prevalence
for mtDNA LHON mutations was 11.82 per 100,000 (95% CI 10.38–13.27 per 100,000). These results indicate
that LHON is not rare but has a population prevalence similar to autosomally inherited neurological disorders.
The majority of individuals harbored only mutant mtDNA (homoplasmy), but heteroplasmy was detected in ∼12%
of individuals. Overall, however, ∼33% of families with LHON had at least one heteroplasmic individual. The
high incidence of heteroplasmy in pedigrees with LHON raises the possibility that a closely related maternal relative
of an index case may not harbor the mtDNA mutation, highlighting the importance of molecular genetic testing
for each maternal family member seeking advice about their risks of visual failure.
Introduction
Leber hereditary optic neuropathy (LHON [MIM
535000]) characteristically presents with subacute,
painless bilateral visual failure in young adults, and it
results from the focal degeneration of the retinal gan-
glion cell layer and optic nerve (Leber 1871; Seedorff
1985). More than 95% of individuals with LHON har-
bor one of three mtDNA “primary” point mutations,
all of which affect genes encoding complex I subunits
of the respiratory chain (Mackey et al. 1996). The
G11778A mutation results in an arginine-to-histidine
substitution at amino acid position 340 (R340H) of the
ND4 subunit (Wallace et al. 1988); the G3460A mu-
tation causes an A52T substitution in the ND1 subunit
(Howell et al. 1991; Huoponen et al. 1991); and the
T14484C mutation causes a M64V substitution in the
ND6 subunit (Johns et al. 1992a; Mackey and Howell
1992). Other mtDNA mutations are thought to cause
LHON, but these appear to be relatively rare within the
population (Man et al. 2002). The most striking feature
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of LHON is the marked incomplete penetrance and sex-
specific bias of this mitochondrial disorder. Only ∼50%
of the males and ∼10% of the females who harbor one
of these mutations actually develop the optic neuropathy
(Harding et al. 1995; Riordan-Eva et al. 1995). This
pattern clearly indicates that other genetic and/or en-
vironmental factors must be important in modulating
the phenotypic expression of LHON (Howell 1999).
The three primary pathogenic mutations were all
identified more than a decade ago. Although the clinical
features of LHON have been described in several case
series, there are no well-established prevalence figures
for genetically confirmed cases in the general population
(Man et al. 2002). Many of the previous molecular stud-
ies of large cohorts of patients with LHON were per-
formed in tertiary referral centers with a special interest
in mitochondrial disorders. Patients came from wide
and overlapping geographical areas and were referred
by a large number of clinicians. The complex referral
patterns and the lack of patient follow-up confounded
any attempt to derive robust prevalence figures for
LHON. It is also possible that the methods of case
ascertainment influenced the observed frequency of
mtDNA heteroplasmy in these LHON cohorts. To
address these problems, we performed a rigorous
population-based clinical and molecular study of
LHON in a defined geographical region, the North
East of England.
334 Am. J. Hum. Genet. 72:333–339, 2003
Figure 1 Map of the British Isles, showing the North East Government Office region of England
Subjects, Material, and Methods
Study Population
The North East Government Office region of England
includes Tyne and Wear, Durham, Northumberland, and
Teesside (fig. 1). We used the most recently published
census data for the North East Government Office region
to determine the point prevalence on June 30, 1998
(midyear period); 2,173,800 children and adults !65
years of age were living in the region, 48% of them being
male (Office for National Statistics 2000). This region
has been relatively stable in terms of migratory flux, and
it consists principally of white individuals of Northern
European extraction (Vanderpump et al. 1995). The ep-
idemiological component of this study was limited to
adults below pensionable age, for two reasons. First,
although it is well recognized that LHON may present
in the 7th and 8th decades, this is extremely rare
(Nikoskelainen et al. 1996). Furthermore, it can be dif-
ficult to distinguish between LHON and optic atrophy
secondary to other causes, such as anterior ischemic op-
tic neuropathy or glaucoma among the elderly, even if
there is a clear family history of LHON. Second, the
group that is !65 years of age corresponds to persons
of “working age,” a census group that is defined by the
Office for National Statistics for the United Kingdom
(Office for National Statistics 2000).
Case Ascertainment
For 110 years, patients who present with unexplained
visual failure or suspected LHON have been referred,
as part of routine clinical practice, to the Northern
Genetics Service based in Newcastle upon Tyne by
clinicians throughout the region. Diagnostic mitochon-
drial genetic analysis was then performed within the De-
partment of Neurology, The Medical School, University
of Newcastle upon Tyne. We prospectively collected clin-
ical data and DNA samples from these individuals
throughout the region during the ∼12-year period from
January 1990 to May 2002. Before DNA analysis, all
affected individuals were assessed clinically by an oph-
thalmologist or neurologist who documented subacute
visual failure and excluded structural, metabolic, toxic,
and inflammatory causes. A clinical diagnosis of LHON
was confidently made in some cases, but a large number
of patients with unexplained optic neuropathy were also
referred for investigation and were included in the pre-
sent study. We were deliberately overinclusive in our
selection criteria, to ensure optimal ascertainment of
LHON cases. We restricted our molecular genetic studies
to the three primary mtDNA mutations (G11778A,
G3460A, and T14484C) because these mutations ac-
count for the vast majority (195%) of cases and are an
undisputed cause of LHON (Mackey et al. 1996; Howell
et al. 1998). Other mutations are rare, most have been
described in only one pedigree, and not all of these mu-
tations are acknowledged to be primarily responsible for
the optic neuropathy (Man et al. 2002). After the definite
diagnosis of LHON in a proband, further details about
other family members were actively sought, and, if the
latter consented, they underwent further investigation
by a clinician and provided blood samples for DNA
analysis. Affected and at-risk individuals were included
only if they lived within the North East Government
Office region of England.
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Table 1
Primers and Nucleotide Combinations Used for Primer Extension Reaction
Gene Base Substitution
Sequence
(5′r3′) Strand
5′
Label
Length
(bp)
Product Size
(bp) dNTP ddNTP
ND1 3460 GrA GCTCTTTGGTGAAGAGTTTTATGG Heavy FAM 24 W p 26
M p 25
C G and T
ND4 11778 GrA AGTCCTTGAGAGAGGATTATGATG Heavy ROX 24 W p 26
M p 25
C G and T
ND6 14484 TrC CTGTAGTATATCCAAAGACAACCA Light HEX 24 W p 25
M p 27
C A and T
NOTE.—Primers were synthesized by MWG Biotech, with ROX (red), HEX (green) and FAM (blue) fluorescent tags at the 5′ end. W p
wild-type; M p mutant; dNTPs p deoxynucleotides; ddNTPs p dideoxynucleotides.
Mutation Detection
Total genomic DNA was extracted from peripheral
blood leukocytes, using established methods. The three
primary LHON mutations (G11778A, G3460A, and
T14484C) were detected either by direct mtDNA se-
quencing or RFLP analysis of PCR fragments (Riordan-
Eva and Harding 1995; Black et al. 1996).
Noncoding Control Region Sequencing
The noncoding control region of the mtDNA genome
(D loop) was sequenced in the index patient by PCR
amplification of three overlapping segments, using for-
ward and reverse M13-tagged primer pairs (Andrews et
al. 1999). PCR products were purified (Qiagen) and se-
quenced bidirectionally on an ABI 377 DNA sequencer
by the standard dideoxy chain–termination procedure,
using Big-Dye terminator kits (Perkin Elmer). The raw
sequence data were compared with the revised Cam-
bridge reference sequence (CRS) (Andrews et al. 1999),
using Factura (v. 1.2) and Sequence Navigator (v. 1.0)
softwares (Perkin Elmer). This allowed identification of
the nucleotide changes present in the D loop.
Quantification of Heteroplasmy
Heteroplasmy was determined in each individual by
primer extension assay (PEA), as described elsewhere
(Fahy et al. 1997). A 700-bp PCR fragment encom-
passing each LHON mutation was generated with the
M13-tagged primers used for sequencing and with
AmpliTaq DNA polymerase (Perkin Elmer) under the
following conditions: 95C denaturation for 5 min, fol-
lowed by 30 cycles of 95C for 1 min, 58C for 1 min,
and 72C for 1 min; the last cycle involved a final ex-
tension step at 72C for 10 min. Residual nucleotides in
the PCR mixtures were dephosphorylated by adding 1
U of calf intestinal alkaline phosphatase (CIAP) and 5.0
ml of #10 CIAP buffer and incubating for 30 min at
37C in a thermal cycler. After this step, 1.1 ml of 0.25
M EDTA (pH 8.0) was added, and the CIAP was de-
natured at 75C for 10 min. Double-stranded PCR frag-
ments were purified with QIAquick columns (Qiagen)
and then were used as templates for PEA. Fluorescence-
labeled oligonucleotide primers have been designed that
bind to the mtDNA template adjacent to the mutation
site (table 1). The principle of PEA is simply to extend
this primer for a variable length, depending on the pres-
ence or absence of the LHON mutation, by using a spe-
cific mixture of chain-extending deoxynucleotides and
chain-terminating dideoxynucleotides. Primer extension
reactions were performed in a total volume of 8.0 ml
containing 1.5 ml of the purified PCR template, 40 fmol
of primer, 200 pmol of each of the relevant dNTPs and
ddNTPs, 1.0 U of thermosequenase DNA polymerase,
and 1.5 mM MgCl2 in 1# PCR buffer. After an initial
denaturation step at 95C for 2 min, the reaction con-
ditions comprised 20 cycles of 95C for 20 s and 55C
for 40 s. A 2.0-ml sample of each PEA was mixed with
1.5 ml deionized formamide, 0.5 ml ROX-350 size stan-
dard (Perkin Elmer), and 1.5 mml of EDTA loading buf-
fer (Perkin Elmer); the sample was denatured at 95C
for 5 min before immediate quenching on ice. The wild-
type and mutant products were accurately sized by
electrophoretic separation in a 12% denaturing poly-
acrylamide gel, using an ABI 373 genetic analyzer. The
relative-fluorescence signals of the PEA products were
then analyzed by Genescan (v. 3.0) and Genotyper (v.
2.1) software to quantify the relative allele proportions
and, hence, the level of heteroplasmy.
Statistical Analysis
Group comparisons were performed using the x2 test,
Student’s t test, and one-way analysis of variance, with
95% CI being determined as appropriate (Altman 1991).
Results
Minimum Prevalence of LHON
We identified 16 genealogically unrelated pedigrees
with LHON with at least one affected family member
(table 2). In total, we identified 82 individuals with visual
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Table 2
mtDNA D-Loop Sequences for Pedigrees with LHON in the North East of England
Pedigree D-Loop Nucleotide Changes
3460-(A) A16183C, C16184C, T16189C, T16519C, A263G, CCC303ins (hetero), C311ins
3460-(B) A16343G, G16390A, T16519C, A73G, C150T, A263G, CC303ins, C311ins
3460-(C) C16167T, G16274A, T16304C, A73G, A263G, C303ins, C311ins, C456T
3460-(D) T16519C, A263G, C303ins, C311ins
3460-(E) T16224C, T16311C, T16519C, A73G, T146C, T152C, A263G, C311ins, C324T
11778-(A) C16069T, T16126C, C16193T, C16278T, A73G, C150T, T152C, A263G, C295T, CC303ins, C311ins, C353ins, T489C
11778-(B) C16167T, C16179T, A73G, A263G, T283C, CC303ins, C311ins
11778-(C) C16069T, T16126C, C16193T, C16278T, A73G, C150T, T152C, A263G, C295T, CC303ins (hetero), C311ins, C353ins, T489C
11778-(D) T152C, T193C, A263G, C303ins, C311ins, AC515-516del
11778-(E) T16224C, T16311C, T16519C, A73G, C150T, A263G, C311ins, C497T
11778-(F) T16224C, T16311C, T16519C, A73G, T146C, T152C, A263G, C311ins, C494del
11778-(G) T16519C, A263G, C 311 ins, AC515-516del
11778-(H) T16362C, T152C, T239C, A263G, C303ins, C311ins, AAA335-337del
11778-(K) C16069T, T16126C, T16519C, A73G, G185A, A188G, T195C, G228A, A263G, C295T, CC303ins (hetero), C311ins, C642T,
T489C, AC515-516del
11778-(L) C16069T, T16126C, C16278T, C16287T, A16293G, C16380T, A73G, C150T, T152C, A153G, C295T, C311ins, T489C, C568ins
14484-(A) C16069T, T16126C, C16261T, T16519C, A73G, T146C, G185A, A188G, C222T, G228A, A263G, C295T, C311ins, C462T,
T489C
NOTE.—All nucleotide positions refer to that of the CRS mtDNA light strand. Positions of insertions and deletions in homopolymeric tracts
correlate to the position of the first residue of the respective repeat sequence.
failure attributable to LHON in these families. Seventy
of these individuals were clinically affected and alive
during the midyear period of 1998, giving a minimum
point prevalence of 3.22 per 100,000 for the population
(95% CI 2.47–3.97 per 100,000). When adult males
were considered separately, the minimum point preva-
lence was 7.11 per 100,000 (95% CI 5.49–8.73 per
100,000). Two of the 16 pedigrees—11778-(A) and
11778-(C)—shared identical sequences in the noncoding
D-loop region (table 2), suggesting that they both de-
scended from a common maternal ancestor who har-
bored the G11778A mutation. The remaining families
had distinctly different D-loop sequences, indicating that
the primary LHON mutations arose on a number of
different occasions within the North East of England.
The relative frequency of each primary LHON mutation
was as follows: G11778A, 60% (9 of 15 genetically
independent maternal pedigrees); G3460A, 33% (5 ped-
igrees); and T14484C, 7% (1 pedigree). We were able
to establish a de novo mutation in only one family with
an affected individual harboring the G3460A mutation.
The mutation could not be identified in a blood sample
from the patient’s mother, who shared an identical non-
coding region sequence with the proband.
Minimum Prevalence of LHON Mutations
Pedigree analysis identified a total of 257 living ma-
ternal relatives who either harbored a primary patho-
genic mutation or were direct maternal descendants of
a woman who was homoplasmic for the LHON mu-
tation. The combined minimum point prevalence of
LHON mutations in the population was estimated at
11.82 per 100,000 (95% CI 10.38–13.27 per 100,000).
Sex-Specific Distribution, Penetrance, and Age
at Onset
We observed the characteristic predominance of af-
fected males and sex-specific penetrance of LHON (table
3). The mean age at onset was 22.0 years (SD 13.6), and
195% of patients were affected at the age of 50 years.
There was no statistically significant difference in age at
onset between males and females ( , )Tp 0.45 P 1 .05
or between the three primary LHON mutations (Fp
1, 5). Therefore, we pooled the clinical data to0.5 P 1 .0
generate a cumulative distribution curve (fig. 2).
Incidence of Heteroplasmy
At least one heteroplasmic individual was identified
in 40% of the families with G3460A and in 33% of the
families with G11778A. No heteroplasmic individuals
were identified in the single T14484C family. Overall,
33% of families with LHON in the North East of Eng-
land included at least one individual who was hetero-
plasmic for the primary LHON mutation. When indi-
viduals were considered separately, 9% of those with the
G3460A mutation and 16% of those with the G11778A
mutation were heteroplasmic, giving an overall fre-
quency of 12% for individuals who harbor primary
LHON mutations in the North East of England. None
of the affected individuals harbored !40% mutant
mtDNA in their blood leukocytes.
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Figure 2 Cumulative age at onset of LHON in the North East
of England.
Table 3
Sex-Specific Bias and Penetrance of the Primary LHON Mutations
MUTATION
NO. OF AFFECTED
SEX RATIO (95% CI)
PENETRANCE (95% CI) AMONG
Men Women Men Women
G3460A 19 11 1.73:1 (.78–4.02) 48.7 (32.4–65.2) 28.2 (15.0–44.9)
G11778A 41 8 5.13:1 (2.37–12.66) 50.6 (39.3–61.9) 8.5 (3.71–6.1)
T14484C 3 0 NAa 37.5 (8.5–75.5) 0 (0–45.9)
Overall 63 19 3.32:1 (1.96–5.87) 49.2 (40.3–58.2) 13.7 (8.4–20.5)
a NA p Not applicable.
Discussion
We have performed the first population-based clinical
and molecular genetic epidemiological study of LHON.
In contrast to our previous report of mtDNA LHON
mutations, which involved patients referred with the
most stringent selection criteria (Chinnery et al. 2000),
in the present study we optimized ascertainment by also
investigating patients with unexplained optic neuropa-
thy. The most striking finding is the high prevalence of
LHON within the North East of England. LHON affects
at least 1 in 31,054 individuals, and ∼1 in 8,500 harbor
a primary LHON mutation. When male adults are con-
sidered separately, at least 1 in 14,067 men within this
region have visual failure due to LHON. These figures
are higher than those reported in the premolecular era
(Mackey and Buttery 1992), and they establish LHON
as one of the most common mitochondrial disorders, at
3.22 per 100,000 (Chinnery et al. 2000). LHON is ap-
proximately as common as blindness due to autosomal
dominant optic atrophy (MIM 165500), which has a
prevalence of 3.5 per 100,000 (Kjer et al. 1996); how-
ever, it is less common than visual impairment due to
retinitis pigmentosa (MIM 268000), which affects 21
per 100,000 (Bunker et al. 1984). The prevalence of
LHON is comparable to that of inherited neurological
disorders such as Huntington disease (MIM 143100)
(6.4 per 100,000, according to Morrison et al. [1995])
and to Duchenne muscular dystrophy (MIM 310200)
(3.2 per 100,000) and myotonic dystrophy (MIM
160900) (5.0 per 100,000), according to Emery [1991]).
This finding has implications for the distribution of
health care resources and the management of inherited
eye diseases. Individuals with LHON have special re-
quirements because of the characteristic pattern of visual
failure, the strict maternal inheritance pattern, and the
difficult nature of genetic counseling for unaffected car-
riers (Man et al. 2002). Some studies have also raised
the possibility that specific treatments may enhance the
rate of visual recovery in patients with LHON (Mashima
et al. 2000).
Before extrapolating these data to other populations,
it is important to consider whether the spectrum of dis-
ease due to the primary LHON mutations is unusual in
the North East of England. The sex-specific bias, pen-
etrance, and age at onset for the primary LHON mu-
tations within our region (table 3) were similar to those
reported in other populations (Newman et al. 1991;
Johns et al. 1992b, 1993; Harding et al. 1995; Mac-
millan et al. 1998). There were minor differences in the
mean values; however, these did not reach statistical
significance, and they are more likely due to the small
sample sizes involved (type 1 error). It is well recognized
that the frequency of the different primary LHON mu-
tations varies throughout the world. For example, the
T14484C mutation is the most common cause of
LHON in French-Canadian families (Macmillan et al.
2000), but it is rare in the Japanese population (Mash-
ima et al. 1998). Although we identified only one ped-
igree with T14484C in the North East of England, this
would be predicted on the basis of the proportion of
T14484C pedigrees reported in a large multinational
cohort of pedigrees with LHON from Northern Europe
and Australia (Mackey et al. 1996). It is therefore rea-
sonable to conclude that the observations that we have
made in the North East of England do have broader
relevance for LHON in other populations. Our analyses
identified only one de novo primary LHON mutation.
This is in accordance with the established view that de
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novo LHON mutations are rare (Biousse et al. 1997).
To our knowledge, this is the first reported case of the
de novo G3460A mutation.
Although there are well-established risks of visual
failure in the maternal relatives of a proband with
LHON (Harding et al. 1995; Macmillan et al. 1998),
our observations highlight the importance of perform-
ing molecular genetic analysis on unaffected carriers
who seek guidance on their future risk of visual failure
or of having affected offspring. The potential pitfalls
are illustrated by one of our pedigrees (11778-[A]). De-
spite the fact that the majority of individuals in this
extensive pedigree are homoplasmic for the G11778A
mutation in blood, one branch of the family completely
lost the mutation, and another branch of the family is
heteroplasmic (11778-[C]). In the present study as a
whole, at least one in three families who harbor a pri-
mary LHON mutation had one individual who was
heteroplasmic for the mtDNA mutation. Given that het-
eroplasmy may influence the risk of visual failure and
the risk of maternal transmission of the mtDNA defect
(Smith et al. 1993; Black et al. 1996; Chinnery et al.
2001), confident presymptomatic counseling is possible
only after molecular genetic testing in the individual
concerned. It is then possible to use well-established age-
and sex-specific penetrance data for accurate counseling
of an individual known to harbor a primary LHON
mutation (Harding et al. 1995; Macmillan et al. 1998).
In conclusion, the present study shows that LHON
is not a rare disorder and that it is essential to put into
place the necessary resources for the optimal manage-
ment of these patients and their families. Heteroplasmy
is common in families with LHON, and molecular ge-
netic analysis is mandatory for all maternal relatives
seeking guidance about the risks of visual failure for
themselves and their offspring.
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